WHWK Whitehawk Therapeutics, Inc. Insider Trading

CFO Giacobello sells 218,600 shares (42.5% reduction) across 2 transactions for $882,028 at avg $4.03; stock +7.9% in 30 days but company burned $17.7M net, revenue -72.5% YoY.

CFO Scott M. Giacobello executed 2 separate sales totaling 218,600 shares for $882,028.00, reducing his holdings by 42.5% from 513,824 to 295,224 shares. The sales occurred on 2026-04-15 and 2026-04-16 at blended average price $4.03, while current price stands at $4.11. This substantial reduction in the CFO's position coincides with severe operational distress: the company reported zero revenue in the latest quarter, a net loss of $-17,746,000.00, and annual revenue contraction of -72.5% year-over-year. Despite the stock's recent recovery (+7.9% over 30 days, +41.2% over 90 days), the underlying financial deterioration raises questions about the sustainability of that price appreciation and the timing of this large insider liquidation against the company's loss trajectory.

CEO Lennon David James sold 260,427 shares across 3 sales (Apr 6–8) for $899,537.86; holds 533,122 shares post-sale.

Lennon David James, as Chief Executive Officer of Whitehawk Therapeutics, executed 3 separate sales totaling 260,427 shares for $899,537.86 at an average price of $3.45 between April 6–8, 2026, reducing his holdings by 32.8% from 793,549 to 533,122 shares. The company faces severe financial distress: Revenue was $0.00 in the latest quarter, full-year net income was $-17,746,000.00, annual revenue growth contracted by -72.5%, and the stock has fallen 16.4% from its 52-week high. The CEO's substantial reduction of his equity stake during a period of operational and financial deterioration, combined with the firm's unprofitability and revenue collapse, creates material investor concern about his confidence in the company's trajectory.